Safety and Tolerability Study for Age-Related Macular Degeneration

NCT01485588 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: hI-con1™ 60µl
DRUG: hI-con1™ 150µl
DRUG: hI-con1™ 300µl

Sponsor

Iconic Therapeutics, Inc.